Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 22/74 ]
NASDAQ | Common Stock
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States.
It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.
The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies.
The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth.
In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein.
Daré Bioscience, Inc. is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.55 Decreased by -511.11% | -0.73 Increased by +24.66% |
| Aug 8, 24 | -0.88 Decreased by -780.00% | 0.02 Decreased by -4.50 K% |
| May 14, 24 | -0.07 Increased by +22.22% | -0.06 Decreased by -16.67% |
| Mar 28, 24 | -0.06 Increased by +68.42% | -0.10 Increased by +40.00% |
| Nov 9, 23 | -0.09 Decreased by -12.50% | -0.10 Increased by +10.00% |
| Aug 10, 23 | -0.10 Decreased by -2.18 K% | -0.10 |
| May 11, 23 | -0.09 Increased by +10.00% | -0.10 Increased by +10.00% |
| Mar 30, 23 | -0.19 Decreased by -5.56% | -0.14 Decreased by -35.71% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 41.69 K Decreased by -95.83% | -4.70 M Increased by +43.34% | Decreased by -11.28 K% Decreased by -1.26 K% |
| Jun 30, 24 | 22.44 K Increased by +N/A% | 12.91 M Increased by +247.34% | Increased by +57.54 K% Decreased by N/A% |
| Mar 31, 24 | 9.30 K Increased by +N/A% | -6.76 M Increased by +12.29% | Decreased by -72.62 K% Decreased by N/A% |
| Dec 31, 23 | 1.81 M Decreased by -99.98% | -5.06 M Decreased by -101.20% | Decreased by -279.75% Decreased by -6.73 K% |
| Sep 30, 23 | 1.00 M Increased by +N/A% | -8.30 M Decreased by -20.26% | Decreased by -829.91% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -8.76 M Decreased by -2.22 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -7.70 M Increased by +8.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 10.00 B Increased by +N/A% | 421.69 M Increased by +4.52 K% | Increased by +4.22% Decreased by N/A% |